Insugen 30/70 Injection 100 IU/ml is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. The combination provides both intermediate-acting and short-acting insulin components, facilitating improved glycemic control by addressing both basal and prandial insulin requirements. Insulin isophane acts as an intermediate-acting insulin, offering a prolonged duration of action to maintain basal insulin levels, while the human insulin component provides rapid onset to manage postprandial glucose excursions. This balanced formulation is typically administered subcutaneously to achieve optimal blood glucose regulation in patients with type 1 or type 2 diabetes when oral hypoglycemic agents are insufficient. The onset of action generally occurs within 30 minutes, with peak effects observed between 2 to 12 hours, and a duration of activity lasting up to 24 hours, depending on individual patient response. Dosage and administration should be individualized based on patient needs, blood glucose monitoring, and physician guidance. Proper injection technique and rotation of injection sites are recommended to minimize lipodystrophy. Insugen 30/70 Injection should be stored under refrigeration and protected from light to maintain potency and efficacy.